ResMed (RMD) Tops Q4 EPS by 2c, Beats on Revenues
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $224.99 -1.5%
Revenue Growth %: +6.9%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +6.9%
Financial Fact:
Research and development: 34.45M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q4 EPS of $0.77, $0.02 better than the analyst estimate of $0.75. Revenue for the quarter came in at $556.7 million versus the consensus estimate of $555.73 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Barclays says AI trade is maturing, favors greater diversification
- Corpay agrees to $100M FTC settlement over marketing practices
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
